Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.

Abstract:

:Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women initiating tamoxifen. We performed CYP2D6 genotyping using the AmpliChip CYP450 test and correlated inherited genetic polymorphisms in CYP2D6 and tamoxifen-induced hot flashes. Intermediate metabolizers had greater mean hot flash scores after 4 months of tamoxifen therapy (44.3) compared to poor metabolizers (20.6, P = 0.038) or extensive metabolizers (26.9, P = 0.011). At 4 months, we observed a trend toward fewer severe hot flashes in poor metabolizers compared to intermediate plus extensive metabolizers (P = 0.062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy.

authors

Henry NL,Rae JM,Li L,Azzouz F,Skaar TC,Desta Z,Sikora MJ,Philips S,Nguyen AT,Storniolo AM,Hayes DF,Flockhart DA,Stearns V,Consortium on Breast Cancer Pharmacogenomics Investigators.

doi

10.1007/s10549-009-0309-1

subject

Has Abstract

pub_date

2009-10-01 00:00:00

pages

571-5

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

117

pub_type

临床试验,杂志文章,多中心研究
  • Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.

    abstract:PURPOSE:The Chinese bridging study PUFFIN (NCT02896855) aimed to assess consistency of efficacy with CLEOPATRA (NCT00567190), investigating pertuzumab with trastuzumab and docetaxel versus placebo, trastuzumab, and docetaxel in patients with previously untreated HER2-positive locally recurrent or metastatic breast canc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05728-w

    authors: Xu B,Li W,Zhang Q,Shao Z,Li Q,Wang X,Li H,Sun T,Yin Y,Zheng H,Feng J,Zhang H,Lei G,Restuccia E

    更新日期:2020-08-01 00:00:00

  • Phosphocitrate inhibits calcium hydroxyapatite induced mitogenesis and upregulation of matrix metalloproteinase-1, interleukin-1beta and cyclooxygenase-2 mRNA in human breast cancer cell lines.

    abstract::Microcalcifications containing calcium hydroxyapatite (HA) are often associated with malignant human breast lesions. Frequently, they are the only mammographic features that indicate the presence of a tumoural lesion. We previously reported the induction of both mitogenesis and prostaglandin E2 (PGE2) production and t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1023908307108

    authors: Cooke MM,McCarthy GM,Sallis JD,Morgan MP

    更新日期:2003-05-01 00:00:00

  • Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.

    abstract::Prognosis of early beast cancer is heterogeneous. Today, no histoclinical or biological factor predictive for clinical outcome after adjuvant anthracycline-based chemotherapy (CT) has been validated and introduced in routine use. Using DNA microarrays, we searched for a gene expression signature associated with metast...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1003-z

    authors: Bertucci F,Borie N,Roche H,Bachelot T,Le Doussal JM,Macgrogan G,Debono S,Martinec A,Treilleux I,Finetti P,Esterni B,Extra JM,Geneve J,Hermitte F,Chabannon C,Jacquemier J,Martin AL,Longy M,Maraninchi D,Fert V,Birnb

    更新日期:2011-06-01 00:00:00

  • Lack of efficacy of xeroradiography to preoperatively detect axillary lymph node metastases in breast cancer.

    abstract::Xeroradiography of the axilla was performed in 132 patients with operable breast cancer to investigate the status of the axillary lymph nodes. Pathologic findings were correlated with the results of clinical examination and xeroradiographic findings. Xeroradiography does not appear to have improved our ability to iden...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01807590

    authors: Coopmans de Yoldi GF,Andreoli C,Costa A,Nessi R,Gilardoni L,Rasponi A

    更新日期:1983-01-01 00:00:00

  • Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?

    abstract:PURPOSE:Primary chemotherapy is commonly used in patients with breast cancer to downstage the primary tumour prior to surgery. There is a need to establish, prior to commencement of chemotherapy, predictors of clinical and pathological response, which may then be surrogate markers for patient survival and thus allow id...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/B:BREA.0000032986.00879.d7

    authors: Ogston KN,Miller ID,Schofield AC,Spyrantis A,Pavlidou E,Sarkar TK,Hutcheon AW,Payne S,Heys SD

    更新日期:2004-07-01 00:00:00

  • Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.

    abstract::We evaluated the question of whether the chemosensitizers verapamil and quinine given orally to breast cancer patients failing combination chemotherapy alone would result in additional clinical responses. In vitro studies reported here showed verapamil sensitization of Adriamycin resistance in 18.8% of fresh human bre...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1005716214718

    authors: Taylor CW,Dalton WS,Mosley K,Dorr RT,Salmon SE

    更新日期:1997-01-01 00:00:00

  • A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.

    abstract::The goal of this study was to compare the efficacy and toxicity of chemotherapy to exemestane plus everolimus (EXE/EVE) through a network meta-analysis (NMA) of randomized controlled trials. NMA methods extend standard pairwise meta-analysis to allow simultaneous comparison of multiple treatments while maintaining ran...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-015-3453-9

    authors: Generali D,Venturini S,Rognoni C,Ciani O,Pusztai L,Loi S,Jerusalem G,Bottini A,Tarricone R

    更新日期:2015-07-01 00:00:00

  • A longitudinal study of shoulder and arm morbidity in breast cancer survivors 7 years after sentinel lymph node biopsy or axillary lymph node dissection.

    abstract::Knowledge about long-term consequences of breast cancer treatment on shoulder and arm function and volume in stages I-II breast cancer survivors is limited. The effects of shoulder-arm function shortly after surgery on long-term function are unknown. One hundred and ninety-four women were examined pre-surgery (T0) and...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2509-y

    authors: Kootstra JJ,Dijkstra PU,Rietman H,de Vries J,Baas P,Geertzen JH,Hoekstra HJ,Hoekstra-Weebers JE

    更新日期:2013-05-01 00:00:00

  • Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors.

    abstract::Treatment decisions in oncology are based on a balance between the efficacy of therapy and its side effects. Patients with metastases and patients with a limited prognosis are a particular challenge, since communication about the disease situation and the expected therapeutic benefit is difficult not only for patients...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2557-3

    authors: Lux MP,Bayer CM,Loehberg CR,Fasching PA,Schrauder MG,Bani MR,Häberle L,Engel A,Heusinger K,Tänzer T,Radosavac D,Scharl A,Bauerfeind I,Gesslein J,Schulte H,Overbeck-Schulte B,Beckmann MW,Hein A

    更新日期:2013-06-01 00:00:00

  • Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells.

    abstract::Electron paramagnetic resonance (EPR) imaging is an emerging modality that can detect and localize paramagnetic molecular probes (so-called spin probes) in vivo. We previously demonstrated that nitroxide spin probes can be encapsulated in liposomes at concentrations exceeding 100 mM, at which nitroxides exhibit a conc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0715-4

    authors: Burks SR,Macedo LF,Barth ED,Tkaczuk KH,Martin SS,Rosen GM,Halpern HJ,Brodie AM,Kao JP

    更新日期:2010-11-01 00:00:00

  • Mutation analysis of PALB2 gene in French breast cancer families.

    abstract::Several population-based and family-based studies have demonstrated that germline mutations of the PALB2 gene (Partner and Localizer of BRCA2) are associated with an increased risk of breast cancer. Distinct mutation frequencies and spectrums have been described depending on the population studied. Here we describe th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3625-7

    authors: Damiola F,Schultz I,Barjhoux L,Sornin V,Dondon MG,Eon-Marchais S,Marcou M,GENESIS Study Investigators.,Caron O,Gauthier-Villars M,de Pauw A,Luporsi E,Berthet P,Delnatte C,Bonadona V,Maugard C,Pujol P,Lasset C,Longy M

    更新日期:2015-12-01 00:00:00

  • Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.

    abstract::Five-year breast cancer survivors, diagnosed after 65 years of age, may develop more incident comorbidities than similar populations free of cancer. We investigated whether older breast cancer survivors have a similar comorbidity burden 6-15 years after cancer diagnosis to matched women free of breast cancer at start ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3021-8

    authors: Jordan JH,Thwin SS,Lash TL,Buist DS,Field TS,Haque R,Pawloski PA,Petersen HV,Prout MN,Quinn VP,Yood MU,Silliman RA,Geiger AM

    更新日期:2014-07-01 00:00:00

  • The nude mouse as an in vivo model for human breast cancer invasion and metastasis.

    abstract::Human breast cancer xenografts only rarely invade and metastasize in nude mice, and have therefore only had limited use as a model for studying mechanisms involved in breast cancer spreading. However, recent reports describe differences not only between various cell lines but also between strains of immune-deficient m...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01833265

    authors: Brünner N,Boysen B,Rømer J,Spang-Thomsen M

    更新日期:1993-01-01 00:00:00

  • A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease.

    abstract::Experimental evidence provides strong support for anti-carcinogenic effects of calcium and vitamin D with respect to breast cancer. Observational epidemiologic data also provide some support for inverse associations with risk. We tested the effect of calcium plus vitamin D supplementation on risk of benign proliferati...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-008-0213-0

    authors: Rohan TE,Negassa A,Chlebowski RT,Ceria-Ulep CD,Cochrane BB,Lane DS,Ginsberg M,Wassertheil-Smoller S,Page DL

    更新日期:2009-07-01 00:00:00

  • Ethanol promotes mammary tumor growth and angiogenesis: the involvement of chemoattractant factor MCP-1.

    abstract::Alcohol consumption is a risk factor for breast cancer in humans. Experimental studies indicate that alcohol exposure promotes malignant progression of mammary tumors. However, the underlying cellular and molecular mechanisms remain unclear. Alcohol induces a pro-inflammatory response by modulating the expression of c...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1902-7

    authors: Wang S,Xu M,Li F,Wang X,Bower KA,Frank JA,Lu Y,Chen G,Zhang Z,Ke Z,Shi X,Luo J

    更新日期:2012-06-01 00:00:00

  • The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome.

    abstract:BACKGROUND:Telomerase is a ribonucleoprotein enzyme that synthesises telomeres in human germ cells, embryogenesis and in cancer, maintaining chromosomal length, stability and cellular immortality. The hTERT gene is the rate-limiting determinant of telomerase reactivation during immortalization and malignant transformat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9622-8

    authors: Salhab M,Jiang WG,Newbold RF,Mokbel K

    更新日期:2008-05-01 00:00:00

  • GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.

    abstract::We investigated the role of glial cell line-derived neurotrophic factor (GDNF) in compensating trastuzumab (TZMB)-induced apoptosis in HER2+ breast cancer (BC) cells using xenograft tumors. We generated BC xenografts in nude mice using samples from three patients selected based on their HER2 status and response to TZM...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-4078-3

    authors: Gardaneh M,Shojaei S,Kaviani A,Behnam B

    更新日期:2017-04-01 00:00:00

  • Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients.

    abstract::Pathological complete response (pCR) is an important predictor of long-term survival in patients with breast cancer receiving neoadjuvant chemotherapy (NAC). At present, the accuracy of traditional radiological assessments during treatment in predicting pCR is poor. Unidimensional and 3D volumetric ultrasound measurem...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1454-x

    authors: Gounaris I,Provenzano E,Vallier AL,Hiller L,Iddawela M,Hilborne S,Taylor K,Britton P,Earl HM,Sinnatamby R

    更新日期:2011-06-01 00:00:00

  • Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.

    abstract::This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-004-4384-z

    authors: Kusama M,Miyauchi K,Aoyama H,Sano M,Kimura M,Mitsuyama S,Komaki K,Doihara H

    更新日期:2004-11-01 00:00:00

  • The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.

    abstract::Breast cancer has been the most common malignant tumor among women in many large cities of China. The aim of this study was to clarify the prognostic significance of serum anti-p53 antibodies (p53 Abs) in Chinese patients of breast cancer. One hundred and forty-four patients with invasive ductal carcinoma of breast we...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-4321-9

    authors: Gao RJ,Bao HZ,Yang Q,Cong Q,Song JN,Wang L

    更新日期:2005-09-01 00:00:00

  • Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).

    abstract:PURPOSE:When combined with anthracyclines, the humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin) provides significant clinical benefit for women with HER2-overexpressing metastatic breast cancer. However, its use is limited by severe cardiotoxicity. To clarify whether myocardial HER2 and HER4 expression i...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/b:brea.0000003916.39959.73

    authors: Fuchs IB,Landt S,Bueler H,Kuehl U,Coupland S,Kleine-Tebbe A,Lichtenegger W,Schaller G

    更新日期:2003-11-01 00:00:00

  • Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

    abstract::Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3608-8

    authors: Oesterreich S,Henry NL,Kidwell KM,Van Poznak CH,Skaar TC,Dantzer J,Li L,Hangartner TN,Peacock M,Nguyen AT,Rae JM,Desta Z,Philips S,Storniolo AM,Stearns V,Hayes DF,Flockhart DA

    更新日期:2015-11-01 00:00:00

  • Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.

    abstract::One of the most efficacious primary therapies in HER2-positive breast cancer was published by the M.D. Anderson group in 2005. This randomized trial evaluated the addition of trastuzumab to a taxane-anthracycline based chemotherapy. Despite largely significant differences in pathological complete response (pCR) in the...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-012-2149-7

    authors: Pernas S,Gil-Gil M,de Olza MO,Gumà A,Climent F,Petit A,Pla MJ,García-Tejedor A,López-Ojeda A,Falo C,Fernandez-Otega A,Mesia C,Pérez-Martin FJ,Urruticoechea A,Germà JR

    更新日期:2012-08-01 00:00:00

  • Ethnic differences in risk perception among women at increased risk for breast cancer.

    abstract::There has been increasing interest in the role of cultural and ethnic factors in breast cancer risk perceptions and screening practices. This study examined ethnic differences in breast cancer risk perception in 112 African American and 224 white women ages 35 and older who had at least one first-degree relative diagn...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/BF01806000

    authors: Hughes C,Lerman C,Lustbader E

    更新日期:1996-01-01 00:00:00

  • Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.

    abstract::A review of the literature finds that women diagnosed with breast cancer, who were on an aspirin regimen, experienced a decreased risk of distant metastases and death. Several recent studies have reported an improvement in overall survival in colorectal cancer patients who harbored mutations in the oncogene PIK3CA and...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3729-8

    authors: Turturro SB,Najor MS,Ruby CE,Cobleigh MA,Abukhdeir AM

    更新日期:2016-02-01 00:00:00

  • MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.

    abstract::Node-positive breast carcinoma is associated with a poor prognosis. Some patients benefit from adjuvant chemotherapy but new treatment modalities should still be developed in order to further increase the cure rate in this patient group. Prognostic factors are needed to define patients for such studies. Here, the prog...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006326513176

    authors: Talvensaari-Mattila A,Pääkkö P,Turpeenniemi-Hujanen T

    更新日期:1999-12-01 00:00:00

  • Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases.

    abstract::Circulating CA 15-3 antigen levels were evaluated in patients with benign diseases and breast cancer patients with no clinical evidence of disease after surgery (NED). Patients with breast cancer NED were followed for tumor recurrence or death during a median of 12.9 months (range 1 to 25 months). CA 15-3 and carcinoe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806524

    authors: Colomer R,Ruibal A,Genollá J,Rubio D,Del Campo JM,Bodi R,Salvador L

    更新日期:1989-03-01 00:00:00

  • Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.

    abstract::Germline mutations in the BRCA1/2 genes account for the majority of hereditary breast ovarian cancer (HBOC). Identification of causal mutations may have significant impact on clinical management of such families. Despite high mutation detection rate, many HBOC cases remain without identified cause. These cases warrant...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1325-x

    authors: Konecny M,Milly M,Zavodna K,Weismanova E,Gregorova J,Mlkva I,Ilencikova D,Kausitz J,Bartosova Z

    更新日期:2011-02-01 00:00:00

  • International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation.

    abstract::The c.156_157insAlu BRCA2 mutation has so far only been reported in hereditary breast/ovarian cancer (HBOC) families of Portuguese origin. Since this mutation is not detectable using the commonly used screening methodologies and must be specifically sought, we screened for this rearrangement in a total of 5,443 suspec...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1036-3

    authors: Peixoto A,Santos C,Pinheiro M,Pinto P,Soares MJ,Rocha P,Gusmão L,Amorim A,van der Hout A,Gerdes AM,Thomassen M,Kruse TA,Cruger D,Sunde L,Bignon YJ,Uhrhammer N,Cornil L,Rouleau E,Lidereau R,Yannoukakos D,Pertesi M

    更新日期:2011-06-01 00:00:00

  • Older women's experience with breast cancer treatment decisions.

    abstract::The purpose of this study was to better understand older women's experience with breast cancer treatment decisions. We conducted a longitudinal study of non-demented, English-speaking women ≥ 65 years recruited from three Boston-based breast imaging centers. We interviewed women at the time of breast biopsy (before th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2921-y

    authors: Schonberg MA,Birdwell RL,Bychkovsky BL,Hintz L,Fein-Zachary V,Wertheimer MD,Silliman RA

    更新日期:2014-05-01 00:00:00